Board of Directors

Neil Crabb

Neil Crabb is Chief Executive of Frontier IP. He co-founded Sigma Capital Group plc and has considerable experience as an investor and director of a wide range of technology and university spin-out companies. He was previously an investment manager at Duncan Lawrie Ltd. with responsibility for a range of managed portfolios investing in smaller UK companies and unquoted technology companies, prior to which he spent four years with Equitable Life Assurance Soc., latterly as investment analyst managing investments in UK small companies and larger stocks in the electronics sector. Neil is an approved person under FSMA.

neil@frontierip.co.uk

Jackie McKay

Jackie is the Group's Chief Operating Officer, supporting the Chief Executive in the delivery of the Group's objectives. She has substantial experience of the university IP and venture capital industries and has been working with Frontier IP since its inception to help develop new and existing commercialisation relationships. Jackie spent nearly ten years at Sigma Capital Group plc, latterly as Corporate Development Director, where she was responsible for structuring and setting up venture funds and university partnerships. Prior to Sigma, Jackie spent 12 years with Bank of Scotland. She has an MA in Psychology.

jackie@frontierip.co.uk

Jim Fish

Jim is Finance Director and Company Secretary of Frontier IP. He has over 25 years' experience in senior financial positions and a wide range of commercial experience including venture capital funded small/medium-sized enterprises and start-up companies. He was latterly interim Finance Director at The One Place Capital Limited, an online technology start-up. He qualified as a chartered accountant with KPMG and holds a degree in Accounting and Finance from Heriot Watt University, Edinburgh.

jim@frontierip.co.uk

David Cairns

David is Portfolio Director at Frontier IP and is responsible for developing and managing its equity and licensing portfolio. David has 25 years' experience in developing technology from concept through to commercialisation. He previously worked for Optos plc, the retinal imaging company, where he was instrumental in building the business from start-up, serving on the board until its flotation on the London Stock Exchange.

david@frontierip.co.uk

Mike Bourne

Mike is a Non-Executive Director of Frontier IP. Mike has almost 30 years' experience in investment management and particular expertise in technology, life sciences and clean technology. He is currently Partner of Accretion Capital LLP and a Director of Cygna Negra Limited, Cygna Negra Malta Limited and Cloudfind Limited. He is also an Advisory Board Member of V2R, the US technology transfer venture company. Prior to these roles, in 1995, he founded asset management company, Reabourne Technology Investment Management Limited, where he was also Chief Investment Officer. For nine years until 2009, he was also a member of the techMARK Advisory Committee.

Andrew Richmond

Andrew Richmond is Non-Executive Chairman of Frontier IP. Andrew has substantial experience of the healthcare, stockbroking and private equity industries. He is Chairman of Hub North Scotland, a Lay Member of the Court of the University of Dundee and a Non-Executive Director of Scotland's Charity Air Ambulance.

Campbell Wilson

Campbell is a Non-Executive Director of Frontier IP. Campbell, who is past Chairman and currently a member of the Board of the UK Pharmaceutical Licensing Group, has worked in the UK pharmaceutical industry for approximately 35 years. The last 17 years of his career were in business development at AstraZeneca, the global research-based biopharmaceutical company, latterly as Executive Business Development Director within the company's central Business Development function. He led strategic collaboration and licensing activities at the unit, driving multiple technology and oncology therapy area collaborations and product licensing deals, including high profile and innovative agreements. Before his involvement in business development, Campbell worked in senior level scientific roles in cardiovascular drug discovery at AstraZeneca, and earlier at Beecham Pharmaceuticals (now GSK).

Email Alerts Subscribe to Our Latest News

Delivered by Investis – link to website (opens in a new window)